Welcome to Open Science
Contact Us
Home Books Journals Submission Open Science Join Us News
Renal Effects of Ibuprofen during the Treatment of Patent Ductus Arteriosus in Low Birth Weight Premature Infants
Current Issue
Volume 2, 2014
Issue 6 (December)
Pages: 123-128   |   Vol. 2, No. 6, December 2014   |   Follow on         
Paper in PDF Downloads: 14   Since Aug. 28, 2015 Views: 1456   Since Aug. 28, 2015
Authors
[1]
Edmond Pistulli, Pediatric Department, University Hospital Center Mother Theresa, Tirana, Albania.
[2]
Alketa Hoxha Qosja, Neonatology Department, University Hospital for Obstetrics and Gynecology, Tirana, Albania.
[3]
Diamant Shtiza, Pediatric Nephrology Department, University Hospital Center Mother Theresa, Tirana, Albania.
[4]
Maks Basho, Imagery Department, University Hospital Center Mother Theresa, Tirana, Albania.
[5]
Gentian Vyshka, Faculty of Medicine, University Hospital Center Mother Theresa, Tirana, Albania.
Abstract
Background: Aim of this study was to assess the efficacy and safety of oral ibuprofen and intravenous ibuprofen for the early pharmacological treatment of patent ductus arteriosus (PDA) in preterm infants. Methods: A randomized, single-blinded, controlled study performed on premature neonates, from January 2010 to December 2012. The study enrolled 68 preterm infants with gestational age between 28-32 weeks, birth weight ≤ 2000 g, postnatal age 48-96 h, and had echocardiographically confirmed significant PDA. The preterm infants received either intravenous or oral ibuprofen randomly as an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h. Serum creatinine (sCr), blood urea nitrogen (BUN) and urine output (UO) were recorded prior to start treatment, and after the course treatment. Results: 36 patients were treated with oral ibuprofen and 32 with intravenous ibuprofen in this period. After the first course treatment, the PDA closed in 30 (83.3%) of the patients assigned to the oral ibuprofen group versus 23 (71.8%) of those enrolled in the intravenous ibuprofen group (p=0.355). In the evaluation of renal tolerance, none of the patients had oliguria. The serum creatinine levels after the first and after the second treatment course did not differ significantly from the baseline for each group. Conclusions: Oral ibuprofen treatment seems to be as efficient as intravenous ibuprofen in closing PDA on the third day of life in low birth weight preterm infants and without significant changes of renal function.
Keywords
Ibuprofen, Patent Ductus Arteriosus, Renal Function, Serum Creatinine Level
Reference
[1]
Lago P, Bettiol T, Salvadori S, Pitassi I, Vianello A, Chiandetti L, Saia OS. Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomised controlled trial. Eur J Pediatr. 2002;161(4):202–7.
[2]
Evans N, Kluckow M. Early ductal shunting and intraventricular haemorrhage in ventilated preterm infants. Arch Dis Child Fetal Neonatal Ed. 1996;75(3):F183–F186.
[3]
Martin CG, Snider AR, Katz SM, Peabody JL, Brady JP. Abnormal cerebral blood flow patterns in preterm infants with a large patent ductus arteriosus. J Pediatr. 1982;101(4):587
[4]
Wong SN, Lo RN, Hui PW. Abnormal renal and splanchnic arterial Doppler pattern in premature babies with symptomatic patent ductus arteriosus. J Ultrasound Med. 1990;9(3):125–30
[5]
Cotton RB, Stahlman MT, Kovar I, Catterton WZ. Medical management of small preterm infants with symptomatic patent ductus arteriosus. J Pediatr. 1978;92(3):467–73.
[6]
Van Overmeire B, Smets K, Lecoutere D, Van de Broek H, Weyler J, Degroote K, Langhendries JP. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med. 2000;343(10):674–681.
[7]
Friedman WF, Hirschklau MJ, Printz MP, Pitlick PT, Kirkpatrick SE. Pharmacologic closure of patent ductus arteriosus in the premature infant. N Engl J Med. 1976;295(10):526–9.
[8]
Heymann MA, Rudolph AM, Silverman NH. Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. N Engl J Med. 1976;295(10):530–3.
[9]
Betkerur MV, Yeh TF, Miller K, Glasser RJ, Pildes RS. Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus. Pediatrics. 1981;68(1):99–102.
[10]
van Bel F, Guit GL, Schipper J, van de Bor M, Baan J. Indomethacin-induced changes in renal blood flow velocity waveform in premature infants investigated with color Doppler imaging. J Pediatr. 1991;118(4 (Pt 1)):621–6
[11]
Edwards AD, Wyatt JS, Richardson C, Potter A, Cope M, Delpy DT, Reynolds EO. Effects of indomethacin on cerebral haemodynamics in very preterm infants. Lancet. 1990;335(8704):1491–5.
[12]
Varvarigou A, Bardin CL, Beharry K, Chemtob S, Papageorgiou A, Aranda JV. Early ibuprofen administration to prevent patent ductus arteriosus in premature newborn infants. JAMA. 1996;275(7):539–44.
[13]
Tiker F, Yildirim SV. Acute renal impairment after oral ibuprofen for medical closure of patent ductus arteriosus. Indian Pediatr. 2007;44(1):54–5.
[14]
Vieux R, Desandes R, Boubred F, Semama D, Guillemin F, Buchweiller MC, Fresson J, Hascoet JM. Ibuprofen in very preterm infants impairs renal function for the first month of life. Pediatr Nephrol. 2010;25(2):267–74.
[15]
Gournay V, Roze JC, Kuster A, Daoud P, Cambonie G, Hascoet JM, Chamboux C, Blanc T, Fichtner C, Savagner C, Gouyon JB, Flurin V, Thiriez G. Prophylactic ibuprofen versus placebo in very premature infants: a randomised, double-blind, placebo-controlled trial. Lancet. 2004;364(9449):1939–44.
[16]
Richards J, Johnson A, Fox G, Campbell M. A second course of ibuprofen is effective in the closure of a clinically significant PDA in ELBW infants. Pediatrics. 2009;124(2):e287–e293.
[17]
Guignard JP. The adverse renal effects of prostaglandin synthesis inhibitors in the newborn rabbit. Semin Perinatol 2002;26:398–405.
[18]
Allegaert K, Vanhole C, de Hoon J, Guignard JP, Tibboel D, Devlieger H, Van Overmeire B. Nonselective cyclo-oxygenase inhibitors and glomerular filtration rate in preterm neonates. Pediatr Nephrol 2005;20:1557–1561..
[19]
R. P. GINIGER, C. BUFFAT, V. MILLET, & U. SIMEONI REVIEW ARTICLE Renal effects of ibuprofen for the treatment of patent ductus arteriosus in premature infants
[20]
Varvarigou A, Bardin CL, Beharry K, Chemtob S, Papageorgiou A, Aranda JV. Early ibuprofen administration to prevent patent ductus arteriosus in premature newborn infants. JAMA 1996;275:539–544.
[21]
Gournay V, Roze JC, Kuster A, Daoud P, Cambonie G, Hascoet JM, Chamboux C, Blanc T, Fichtner C, Savagner C, Gouyoh JB, Flurin V, Thiriez G, et al. Prophylactic ibuprofen versus placebo in very premature infants: A randomised, double-blind, placebo-controlled trial. Lancet 2004;364:1939–1944.
[22]
Van Overmeire B, Allegaert K, Casaer A, Debauche C, Decaluwe´ W, Jespers A, Weyler J, Harrewijn I, Langhendries JP, et al. Prophylactic ibuprofen in premature infants: A multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2004;364:1945–1949.
[23]
Hammerman C, Kaplan M. Primum non nocere: Prophylactic versus curative ibuprofen. Lancet 2004;36:1920–1922.
[24]
Papile LS, Burstein J, Burstein R, Keffler H. Incidence and evolution of the subependymal intraventricular hemorrhage: a study of infants weighing less than 1500 grams. J Pediatr.1978;92 :529– 534
[25]
Kauffman RE, Nelson MV. Effect of age on ibuprofen pharmacokinetics and antipyretic response. J Pediatr.1992;121 :969– 973
[26]
Kelley MT, Walson PD, Edge JH, Cox S, Mortensen ME. Pharmacokinetics and pharmacodynamics of ibuprofen isomers and acetaminophen in febrile children. Clin Pharmacol Ther.1992;52 :181– 189
[27]
Cherif A, Jabnoun S, Khrouf N. Oral ibuprofen in early curative closure of patent ductus arteriosus in very premature infants. Am J Perinatol.2007;24 (6):339– 345
[28]
Hariprasad P, Sundarrajan V, Srimathy G, Suthager B, Ramadevi BS. Oral ibuprofen for closure of hemodynamically significant PDA in premature neonates. Indian Pediatr.2002;39 (1):99– 100
[29]
Sangtawesin V, Sangtawesin C, Raksasinborisut C, et al. Oral ibuprofen prophylaxis for symptomatic patent ductus arteriosus of prematurity. J Med Assoc Thai.2006;89 (3):314– 321
[30]
Aly H, Lotfy W, Badrawi N, Ghawas M, Abdel-Meguid IE, Hammad TA. Oral ibuprofen and ductus arteriosus in premature infants: a randomized pilot study. Am J Perinatol.2007;24 (5):267– 270
[31]
Fakhraee SH, Badiee Z, Mojtahedzadeh S, Kazemian M, Kelishad R. Comparison of oral ibuprofen and indomethacin therapy for patent ductus arteriosus in preterm infants. Zhongguo Dang Dai Er Ke Za Zhi.2007;9 (5):399– 403
[32]
Supapannachart S, Limrungsikul A, Khowsathit P. Oral ibuprofen and indomethacin for treatment of patent ductus arteriosus in premature infants: a randomized trial at Ramathibodi Hospital. J Med Assoc Thai.2002;85 (suppl 4):S1252– S1258
[33]
Chotigeat U, Jirapapa K, Layangkool T. A comparison of oral ibuprofen and intravenous indomethacin for closure of patent ductus arteriosus in preterm infants. J Med Assoc Thai.2003;86 (suppl 3):S563– S569
[34]
Heyman E, Morag I, Batash D, Keidar R, Baram S, Berkovitch M. Closure of patent ductus arteriosus with oral ibuprofen suspension in premature newborns: a pilot study. Pediatrics.2003;112 (5).
[35]
Cherif A, Khrouf N, Jabnoun S, Mokrani C, Amara MB, Guellouze N, et al Randomized pilot study comparing oral ibuprofen with intravenous ibuprofen in very low birth weight infants with patent ductus arteriosus. Pediatrics 2008; 122: 1256-61.
[36]
Gokmen T, Erdeve O, Altug N, et al. Efficacy and safety of oral versus intravenous ibuprofen in very low birth weight preterm infants with patent ductus arteriosus. J pediatr 2011; 158:549-554 e1.
[37]
Erdeve O, Gokmen T, Altug N, et al. Oral versus intravenous ibuprofen: which is better in closure of patent ductus arteriosus? Pediatrics 2009; 123:e763
Open Science Scholarly Journals
Open Science is a peer-reviewed platform, the journals of which cover a wide range of academic disciplines and serve the world's research and scholarly communities. Upon acceptance, Open Science Journals will be immediately and permanently free for everyone to read and download.
CONTACT US
Office Address:
228 Park Ave., S#45956, New York, NY 10003
Phone: +(001)(347)535 0661
E-mail:
LET'S GET IN TOUCH
Name
E-mail
Subject
Message
SEND MASSAGE
Copyright © 2013-, Open Science Publishers - All Rights Reserved